Chen Dongmiao, Zhang Yajie, Wu Xiaoqiong, Wu Jiewen, Gong Fengying, Qiao Lin, Li Li, Wang Congrong
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Department of Laboratory, Xintang Hospital, Guangzhou 511340, China.
Ann Palliat Med. 2020 Jan;9(1):70-81. doi: 10.21037/apm.2019.12.11.
In 2014, a serious dengue outbreak occurred in Guangzhou, South China. In this study, the clinical and laboratory characteristics of dengue fever (DF) group and other febrile illnesses (OFI) group in Guangzhou were described.
Clinical and laboratory data collected by studying 1,792 patients from Nanfang Hospital, Southern Medical University during 2014 and 2018. Laboratory data was analyzed by SPSS 22.0 statistical software including Full blood counts (SYSMEX XE-5000), Laboratory Biochemical tests (Roche Cobas 8000), Dengue virus RNA (RT-PCR-Fluorescence Probing) and Dengue IgG/IgM Antibody (Colloidal Gold), Dengue Virus NS1 (ELISA).
In the DF group and OFI group, gender ratios were 1.08:1 (male/female, P>0.05) and 1.45:1 (male/female, P<0.05). Adults aged 25-34 years old (29.4%) with the main peak appeared in the DF group, and the same main peak appeared in the OFI group: 25-34 years old (25.13%). Patients were from Medical emergency (41.2% DF group, 29.4% OFI group). The distribution of fever days before treatment was mainly focused within 5 days, with a main peak in the 2 fever days before treatment (24.6%) in the DF group and the main peak in 1 fever day before treatment (46.9%) in OFI group. The major symptoms of the DF group were presented with were fever (100%), myalgia (34.77%), pharyngeal hyperemia (31.33%), headache (25.65%), adenoids (19.62%), and rash (13.25%). In the OFI group, Pharyngeal hyperemia was the most common clinical symptom, accounting for 27.24%, and the next symptom was adenoids (21.26%). The sensitivity and specificity of DV RNA were 61.54%, 100%, respectively, compared to the DF Nonstructural protein 1 (NS1). Dengue virus (DENV) Immunoglobulin M (IgM) IgM in both groups was statistically significant, with DENV-IgM in the DF group were stronger (Z=-7.863, P<0.001), and DENV immunoglobulin G (IgG) were no statistically significant (Z=-1.212, P=0.226). In DF group, 37.14% of serum samples had elevated Alanine transaminase (ALT) levels, 76.85% of them had elevated aspartate aminotransferase (AST) levels, 32.08% of them had elevated creatine kinase (CK) levels, and 2.67% of them had elevated C-reaction protein (CRP) levels, compared with 13.51% of them had elevated ALT levels, 30.65% of them had elevated AST levels, 6.06% of them had elevated CK levels and 69.35% of them had elevated CRP levels of the OFI patients. The prominent manifestations were thrombocytopenia (occurring in 28.07% of the DF group, compared to 5.18% of OFI group) and leucopenia (occurring in 43.27% of DF group and 3.63% of OFI group). The DF incidence of all fever cases was 49.0% within three months in 2014, compared with 1.4% in 2015, 0% in 2016, 0.9% in 2017 and 6.4% in 2018 (P<0.001). DF and OFI can occur in any age and sex. DF occurred in the young and the old, OFI occurred in children and youth. The clinical symptoms of myalgia, headache, rash, weak, Chills, follicular hyperplasia in both groups were statistically significant (P<0.001).
IgM can be easily recognized for early diagnoses, DENV-RNA had lower sensitivity and higher specificity, and DF NS1 enzyme-linked immunosorbent assay (ELISA) has a higher sensitive and specificity. DF is a serious public health problem and an emerging continuous threat in Guangzhou. In high-prevalence areas, effective epidemic monitoring and prevention measures need to be undertaken. After the unprecedented outbreak in 2014, on account of the government and citizen paying more attention to the DF epidemic, the cases of DF were decreased significantly from 2015 to 2018.
2014年,中国南方的广州市发生了严重的登革热疫情。本研究描述了广州登革热(DF)组和其他发热性疾病(OFI)组的临床和实验室特征。
收集了南方医科大学南方医院2014年至2018年期间1792例患者的临床和实验室数据。实验室数据采用SPSS 22.0统计软件进行分析,包括全血细胞计数(SYSMEX XE - 5000)、实验室生化检测(罗氏Cobas 8000)、登革病毒RNA(RT - PCR荧光探针法)、登革热IgG/IgM抗体(胶体金法)、登革病毒NS1(酶联免疫吸附测定法)。
DF组和OFI组的性别比分别为1.08:1(男/女,P>0.05)和1.45:1(男/女,P<0.05)。DF组中25 - 34岁的成年人占比最高(29.4%),出现了主要高峰,OFI组也出现了相同的主要高峰:25 - 34岁(25.13%)。患者来自医疗急诊(DF组占41.2%,OFI组占29.4%)。治疗前发热天数的分布主要集中在5天内,DF组在治疗前2天发热出现主要高峰(24.6%),OFI组在治疗前1天发热出现主要高峰(46.9%)。DF组的主要症状为发热(100%)、肌痛(34.77%)、咽部充血(31.33%)、头痛(25.65%)、腺样体肿大(19.62%)和皮疹(13.25%)。在OFI组中,咽部充血是最常见的临床症状,占27.24%,其次是腺样体肿大(21.26%)。与DF非结构蛋白1(NS1)相比,DV RNA的敏感性和特异性分别为61.54%、100%。两组中登革病毒(DENV)免疫球蛋白M(IgM)均有统计学意义,DF组的DENV - IgM更强(Z = -7.863,P<0.001),而DENV免疫球蛋白G(IgG)无统计学意义(Z = -1.212,P = 0.226)。DF组中37.14%的血清样本丙氨酸转氨酶(ALT)水平升高,76.85%的天门冬氨酸转氨酶(AST)水平升高,32.08%的肌酸激酶(CK)水平升高,2.67%的C反应蛋白(CRP)水平升高,而OFI组患者中分别有13.51%的ALT水平升高,30.65%的AST水平升高,6.06%的CK水平升高,69.35%的CRP水平升高。突出表现为血小板减少(DF组发生率为28.07%,而OFI组为5.18%)和白细胞减少(DF组发生率为43.27%,OFI组为3.63%)。2014年所有发热病例中DF的发病率三个月内为49.0%,2015年为1.4%,2016年为0%,2017年为0.9%,2018年为6.4%(P<0.001)。DF和OFI可发生于任何年龄和性别。DF在年轻人和老年人中发病,OFI在儿童和青年中发病。两组中肌痛、头痛、皮疹、乏力、寒战、滤泡增生等临床症状均有统计学意义(P<0.001)。
IgM易于识别可用于早期诊断,DENV - RNA敏感性较低但特异性较高,DF NS1酶联免疫吸附测定法具有较高的敏感性和特异性。DF是广州一个严重的公共卫生问题且是一种新出现的持续威胁。在高流行地区,需要采取有效的疫情监测和预防措施。在2014年史无前例的疫情爆发后,由于政府和市民对DF疫情更加关注,2015年至2018年DF病例显著减少。